Clinically and Microbiologically Derived Azithromycin Susceptibility Breakpoints for Salmonella enterica Serovars Typhi and Paratyphi A

Azithromycin is an effective treatment for uncomplicated infections with Salmonella enterica serovar Typhi and serovar Paratyphi A (enteric fever), but there are no clinically validated MIC and disk zone size interpretative guidelines. We studied individual patient data from three randomized control...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Antimicrob Agents Chemother
Auteurs principaux: Parry, Christopher M., Thieu, Nga Tran Vu, Dolecek, Christiane, Karkey, Abhilasha, Gupta, Ruchi, Turner, Paul, Dance, David, Maude, Rapeephan R., Ha, Vinh, Tran, Chinh Nguyen, Thi, Phuong Le, Be, Bay Pham Van, Phi, La Tran Thi, Ngoc, Rang Nguyen, Ghose, Aniruddha, Dongol, Sabina, Campbell, James I., Thanh, Duy Pham, Thanh, Tuyen Ha, Moore, Catrin E., Sona, Soeng, Gaind, Rajni, Deb, Monorama, Anh, Ho Van, Van, Sach Nguyen, Tinh, Hien Tran, Day, Nicholas P. J., Dondorp, Arjen, Thwaites, Guy, Faiz, Mohamed Abul, Phetsouvanh, Rattanaphone, Newton, Paul, Basnyat, Buddha, Farrar, Jeremy J., Baker, Stephen
Format: Artigo
Langue:Inglês
Publié: American Society for Microbiology 2015
Sujets:
Susceptibility
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4394775/
https://ncbi.nlm.nih.gov/pubmed/25733500
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.04729-14
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires